CAP-1002 Yields Significant Upper Limb Improvements in Non-Ambulatory Patients With Later Stage DMD
Data from the HOPE-2-OLE were presented in a late-breaking session at the 2023 MDA Conference.
Non-ambulatory patients with Duchenne muscular dystrophy (DMD) treated with the cardiosphere-derived allogeneic cell therapy CAP-1002 (Capricor Therapeutics) experienced slower progression of decline in Performance of Upper Limb (PUL), according to new data from the open-label extension (OLE; NCT04428476) of the phase 2 HOPE-2 trial (NCT03406780).
These data were presented in a late-breaking session by principal investigator Craig McDonald, MD, chair, department of physical medicine and rehabilitation, and profressor, department of pediatrics and physical medicine and rehabilitation, University of California at Davis, at the2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas.
“We've been excited that there's been results, from this trial and some other recent trials, there's an increased excitement and emphasis on doing clinical trials in this non-ambulatory population,” McDonald said during his presentation.
HOPE-2 assessed participants with a mean age of 14.3 years, all of which were on corticosteroids, and around 80% of which were non-ambulant. Participants were dosed with 150 million CAP-1002 cells intravenouslyevery 3 months.
WATCH NOW: Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy
Preliminary results from the HOPE-2 study were published in The Lancet in 2022 that showed statistically significant slowing of impairment by 70% in PUL1.2 mid-level scale (P = .01; 3.6-point mean difference). On the full PUL 2.0 scale there was a mean 1.8-point difference (P = .04). Investigators also found that left ventricular ejection fraction was higher by a mean 4% delta in treated participants (P = .002) and there was a 107% slowing in disease progression in this factor. No treatment-related serious adverse events (AEs) have been reported in over 100 infusions so far during the OLE. Included in the PUL is hand-to-mouth function, which McDonald singled out as being a key factor in quality-of-life scores in patients with DMD and other muscular dystrophies.
The OLE is assessing CAP-1002 in 13 participants that received either treatment (n = 6) or placebo (n = 7) in HOPE-2, went through a gap phase of a mean 392 days, and were then treated in the OLE. The mean age was 13 years, all patients were non-ambulant, and all were on stable regimen corticosteroids. Patients maintained a treatment benefit for around 3.5 years, which suggests a disease modification effect. Notably, patients treated with placebo in HOPE-2 that had experienced a linear functional decline compared to treated participants experienced a slowing in disease progression to a rate nearly identical to patients previously treated with CAP-1002 in HOPE-2.
CAP-1002 is currently being evaluated in the randomized, blinded, and placebo-controlled phase 3 HOPE-3 trial (NCT05126758) that is enrolling up to 68 participants with DMD to receive 150 million cells every 3 months for a total of 4 doses. The trial is primarily assessing change in full PUL 2.20. Secondary outcome measures include changes in cardiac muscle function and structure by assessing left ventricular ejection fraction, left ventricular end-systolic volume, and left ventricular end-diastolic volume; other individual items in PUL; cardiac inflammation biomarkers; and other disease-modifying effects.
“To conclude, I think this is exciting. The patients on therapy experienced a slower progression of their upper limb deterioration, and this represents an urgency to initiate therapy, as loss of PUL points are never really recovered or regained. There's preserved cardiac function shown in the HOPE-2 trial. The safety profile has been reinforced in over 200 patients treated to date with infusions, and in the open label extension, patients continue to the state to receive CAP-1002. There's now a phase 3 HOPE-3 trial that is currently recruiting patients at multiple centers throughout the US. We don't really view this as an alternative to exon skipping or gene therapy, but I think there could be real potential synergy here with this and the other therapeutics that are emerging in DMD as well as steroids. So, there’s potential to be part of the cocktail treatment,” McDonald concluded his presentation.
Read more coverage of the 2023 MDA Conference here.
